Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach To Combat Multidrug-Resistant Acinetobacter Baumannii
Current Microbiology · 2026-04 · 83 (4)
DOI: 10.1007/s00284-026-04787-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Microbiology, online erschienen am 18.02.2026. Verfasst von Kasra Javadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Curcumin, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Multidrug-resistant (MDR) Acinetobacter baumannii is a major healthcare-associated pathogen with limited treatment options, and the ongoing rise of antibiotic resistance necessitates alternative therapeutic strategies. Curcumin, a bioactive compound derived from Curcuma longa, has demonstrated antimicrobial properties. This study evaluated the in vitro antibacterial activity of curcumin in combination with ceftazidime, imipenem, gentamicin, and ciprofloxacin against clinical MDR A. baumannii isolates. Forty MDR A. baumannii clinical isolates were collected, and their antibiotic susceptibility was confirmed using the Kirby-Bauer disk diffusion method. Broth microdilution assays determined the minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of curcumin and each antibiotic; synergistic interactions were evaluated using checkerboard assays. All isolates were resistant to ceftazidime, imipenem, gentamicin, and ciprofloxacin. In broth microdilution, curcumin alone exhibited a MIC range of 625–2500 µg/mL, while MIC ranges for ceftazidime, imipenem, gentamicin, and ciprofloxacin were 32–512, 8–128, 16–512, and 32–128 µg/mL, respectively. Checkerboard assays revealed synergistic interactions (fractional inhibitory concentration index ≤ 0.5) between curcumin and each antibiotic, with synergy observed in 90% of isolates for curcumin–imipenem, 87.5% for curcumin–ciprofloxacin, 80% for curcumin–ceftazidime, and 72.5% for curcumin–gentamicin. No antagonistic effects were observed. These findings demonstrate that curcumin can potentiate the activity of antibiotics against MDR A. baumannii in vitro; however, due to curcumin’s high concentration requirements and limited systemic bioavailability, further pharmacokinetic/pharmacodynamic studies and optimized formulation strategies are needed to assess its clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran.
- Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran. mhahmadi@shahed.ac.ir.
- Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. ramazan69@yahoo.com.
- Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Zitieren
APA
Javadi, K., Ahmadi, M. H., Rajabnia, M., & Halaji, M. (2026). Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach To Combat Multidrug-Resistant Acinetobacter Baumannii. Current Microbiology, 83(4). https://doi.org/10.1007/s00284-026-04787-4
Vancouver
Javadi K, Ahmadi MH, Rajabnia M, Halaji M. Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach To Combat Multidrug-Resistant Acinetobacter Baumannii. Current Microbiology. 2026;83(4). doi:10.1007/s00284-026-04787-4
BibTeX
@article{Javadi2026,
author = {Javadi, Kasra and Ahmadi, Mohammad Hossein and Rajabnia, Mehdi and Halaji, Mehrdad},
title = {Enhancing Antibiotic Efficacy with Curcumin: A Novel Approach To Combat Multidrug-Resistant Acinetobacter Baumannii},
journal = {Current Microbiology},
year = {2026},
volume = {83},
number = {4},
doi = {10.1007/s00284-026-04787-4}
}
EUVIMED